Recent Research Analysts’ Ratings Updates for Nurix Therapeutics (NRIX)

Nurix Therapeutics (NASDAQ: NRIX) has recently received a number of price target changes and ratings updates:

• 10/21/2024 – Nurix Therapeutics had its price target raised by analysts at HC Wainwright from $26.00 to $30.00. They now have a “buy” rating on the stock.
• 10/21/2024 – Nurix Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
• 10/14/2024 – Nurix Therapeutics had its “overweight” rating reaffirmed by analysts at Stephens. They now have a $31.00 price target on the stock.
• 10/14/2024 – Nurix Therapeutics had its price target lowered by analysts at Royal Bank of Canada from $27.00 to $26.00. They now have an “outperform” rating on the stock.
• 10/14/2024 – Nurix Therapeutics had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
• 10/11/2024 – Nurix Therapeutics is now covered by analysts at Jefferies Financial Group Inc.. They set a “buy” rating and a $41.00 price target on the stock.
• 9/6/2024 – Nurix Therapeutics is now covered by analysts at Robert W. Baird. They set an “outperform” rating and a $26.00 price target on the stock.
• 9/4/2024 – Nurix Therapeutics had its price target raised by analysts at Oppenheimer Holdings Inc. from $27.00 to $30.00. They now have an “outperform” rating on the stock.

Nurix Therapeutics Trading Down 0.5 %

Shares of NASDAQ:NRIX traded down $0.13 during trading on Tuesday, reaching $25.35. 100,654 shares of the company traded hands, compared to its average volume of 892,272. Nurix Therapeutics, Inc. has a 52-week low of $4.22 and a 52-week high of $26.43. The business’s fifty day moving average is $23.81 and its 200-day moving average is $19.73. The firm has a market capitalization of $1.25 billion, a price-to-earnings ratio of -8.68 and a beta of 2.22.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Friday, October 11th. The company reported ($0.67) EPS for the quarter, meeting analysts’ consensus estimates of ($0.67). The company had revenue of $12.59 million during the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 67.78% and a negative net margin of 264.84%. On average, sell-side analysts predict that Nurix Therapeutics, Inc. will post -2.95 earnings per share for the current fiscal year.

Insider Activity

In other news, CFO Houte Hans Van sold 20,000 shares of the business’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $25.22, for a total transaction of $504,400.00. Following the sale, the chief financial officer now owns 31,002 shares in the company, valued at approximately $781,870.44. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, insider Christine Ring sold 3,290 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $25.00, for a total value of $82,250.00. Following the sale, the insider now directly owns 24,592 shares of the company’s stock, valued at approximately $614,800. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Houte Hans Van sold 20,000 shares of Nurix Therapeutics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $25.22, for a total value of $504,400.00. Following the completion of the transaction, the chief financial officer now directly owns 31,002 shares of the company’s stock, valued at approximately $781,870.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 63,105 shares of company stock worth $1,507,181 in the last quarter. 7.20% of the stock is owned by company insiders.

Institutional Trading of Nurix Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of NRIX. ProShare Advisors LLC raised its stake in Nurix Therapeutics by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock valued at $176,000 after buying an additional 998 shares during the last quarter. ClariVest Asset Management LLC increased its position in Nurix Therapeutics by 2.9% during the second quarter. ClariVest Asset Management LLC now owns 63,149 shares of the company’s stock valued at $1,318,000 after acquiring an additional 1,766 shares during the last quarter. Public Employees Retirement System of Ohio boosted its position in Nurix Therapeutics by 3.7% in the first quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock worth $747,000 after purchasing an additional 1,820 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Nurix Therapeutics by 299.8% during the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after purchasing an additional 3,424 shares during the period. Finally, The Manufacturers Life Insurance Company increased its position in shares of Nurix Therapeutics by 25.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,942 shares of the company’s stock valued at $479,000 after purchasing an additional 4,583 shares during the last quarter.

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.